Effects Of Dulaglutide On Visceral Fat And Lipid Metabolism In Overweight Or Obese Patients With Type 2 Diabetes Mellitus

ObjectiveAt present,many studies have confirmed the advantages of dulaglutide in lowering blood glucose,safety and tolerance,but there are few studies about its effects on visceral fat distribution and lipid metabolism.The purpose of this study is to observe the effect of dulaglutide on visceral fat and lipid metabolism in overweight or obese patients with type 2 diabetes mellitus(T2DM)and provide further realistic evidence for the clinical benefit of dulaglutide.MethodsStrictly based on the inclusion and exclusion criteria,overweight or obese patients with type 2 diabetes who were hospitalized in the endocrinology department of Hebei Provincial People’s Hospital from August 1,2021 to October 31,2022 were selected as the research objects.Firstly,the general anthropometric indexes such as height and weight were measured and related indexes such as blood glucose,fasting c-peptide,blood lipid and visceral fat area(VFA)were detected.Dulaglutide 1.5mg was injected subcutaneously once a week.And then,after 12 weeks of medication,the subjects were followed up in the outpatient department of endocrinology,and the above indexes were tested again.Finally,we compared the changes of body weight,waist circumference(WC),body mass index(BMI),fasting plasma glucose(FPG),glycosylated hemoglobin(Hb A1c),fasting c-peptide,blood lipid and VFA before and after treatment.Results1.Changes of body weight,BMI and WC of subjects before and after treatment with dulaglutide:After 12 weeks of treatment,the body weight decreased from the baseline of(94.58±18.32)kg to(85.48±20.33)kg;The BMI decreased from the baseline of(31.85±6.23)kg/m~2to(29.53±5.78)kg/m~2;The WC decreased from the baseline of(103.37±11.22)cm to(97.50±11.80)cm,and these differences were statistically significant(P<0.05).2.Changes of body fat distribution of subjects before and after dulaglutide treatment:VFA decreased from the baseline of(154.32±54.80)cm~2to(119.25±38.87)cm~2;The body fat content decreased from the baseline of(33.99±15.26)kg to(28.59±12.33)kg;The body fat percentage decreased from the baseline of(36.16±8.36)%to(32.78±6.18)%,there were significant differences before and after treatment.(P<0.05).Pearson correlation analysis showed that the change of VFA before and after treatment was positively correlated with baseline VFA,baseline body fat content and baseline body fat percentage(r values were 0.708,0.505,0.609respectively).3.Changes of blood lipid of subjects before and after treatment with dulaglutide:After 12 weeks of treatment,the total cholesterol(TC)decreased from the baseline of(5.45±1.35)mmol/L to(4.58±1.14)mmol/L,and the low-density lipoprotein cholesterol(LDL-C)decreased from the baseline of(3.50±0.80)mmol/L to(2.83±0.78)mmol/L,with significant differences before and after treatment(P<0.05).However,compared with the baseline,there were no significant changes in triglyceride(TG)and high-density lipoprotein cholesterol(HDL-C).4.Changes of blood glucose and fasting c-peptide of subjects before and after treatment with dulaglutide:After 12 weeks of treatment,the fasting plasma glucose decreased from the baseline of(10.11±3.67)mmol/L to(7.55±1.73)mmol/L;The glycosylated hemoglobin decreased from the baseline of(9.08±1.73)%to(6.75±0.70)%;The fasting c-peptide increased from the baseline of(3.11±1.34)ng/m L to(3.72±1.24)ng/m L,and there were significant differences before and after treatment(P<0.05).conclusion1.Dulaglutide can significantly reduce body weight and improve visceral adipose tissue(VAT);2.Dulaglutide has lipid-lowering effect,especially in reducing TC and LDL-C;3.Dulaglutide can significantly reduce FPG and Hb A1c,and can effectively improve the fasting c-peptide level.